Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptasel1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:08:13 ON 18 NOV 2008

=> fil reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 13:08:32 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10517264.str





chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9
normalized bonds :
1-2 1-6 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:08:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   47727 TO ITERATE

  4.2% PROCESSED   2000 ITERATIONS   50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 941495 TO   967585
PROJECTED ANSWERS: 131546 TO   141452

L2   50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:08:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   951522 TO ITERATE

100.0% PROCESSED   951522 ITERATIONS   136136 ANSWERS
SEARCH TIME: 00.00.16

L3   136136 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                        ENTRY   SESSION
FULL ESTIMATED COST   178.36   178.57

FILE 'CAPLUS' ENTERED AT 13:09:18 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l3
L4       38569 L3

=>

=> s l4 and pharmaceutical
        316557 PHARMACEUTICAL
         92562 PHARMACEUTICALS
        371957 PHARMACEUTICAL
                  (PHARMACEUTICAL OR PHARMACEUTICALS)
L5        3160 L4 AND PHARMACEUTICAL

=> s l5 and arthritis
         54947 ARTHRITIS
             2 ARTHRITISES
         54947 ARTHRITIS
                  (ARTHRITIS OR ARTHRITISES)
L6         214 L5 AND ARTHRITIS

=> s l6 and rheumatoid
         39150 RHEUMATOID
            11 RHEUMATOIDS
         39154 RHEUMATOID
                  (RHEUMATOID OR RHEUMATOIDS)
L7         154 L6 AND RHEUMATOID

=> s l7 and cytokine
        120584 CYTOKINE
        158413 CYTOKINES
        209557 CYTOKINE
                  (CYTOKINE OR CYTOKINES)
L8          20 L7 AND CYTOKINE

=> d ibib abs hitstr tot
THE ESTIMATED COST FOR THIS REQUEST IS 109.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y
```

L8 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:125686 CAPLUS
DOCUMENT NUMBER: 148:190136
TITLE: Conjugates of anti-CD70 antibodies with drugs and their use for the treatment of cancer and immune disorders
INVENTOR(S): Law, Che-Leung; Mcearchern, Julie; Drachman, Jonathan G.
PATENT ASSIGNEE(S): Seattle Genetics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 81pp., Cont.-in-part of U.S. Ser. No. 546,304.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080025989	A1	20080131	US 2007-735376		20070413
WO 2004073656	A2	20040902	WO 2004-US5247		20040220
WO 2004073656	A3	20050224			
WO 2004073656	A9	20050901			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20060233794	A1	20061019	US 2005-546304		20050819
PRIORITY APPLN. INFO.:			US 2003-449055P	P	20030220
			WO 2004-US5247	W	20040220
			US 2005-546304	A2	20050819
			US 2006-792127P	P	20060413

AB Conjugates of antibodies to CD70 antigens and cytotoxic compds. that can be used to treat diseases associated with aberrant presentation of the CD70 antigens, including cancers and immune disorders, are described. Preparation of antibody conjugates with auristatin derivs. is described. The conjugates were effective in alleviating the symptoms in the allergic encephalitis model of multiple sclerosis and inhibited tumor growth in a renal cell carcinoma xenograft model.

IT 31430-18-9D, derivs., antibody conjugates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates of anti-CD70 antibodies with drugs and their use for treatment of cancer and immune disorders)

RN 31430-18-9 CAPLUS
CN Carbamic acid, N-[6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)

L8 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:70737 CAPLUS
DOCUMENT NUMBER: 148:168736
TITLE: Preparation of pyrrolopyrimidines having Mnk1/Mnk2 inhibiting activity
INVENTOR(S): Jaekel, Stefan; Reuter, Tanja; Murfin, Stephen; Coulter, Thomas Stephen; Taylor, Steven
PATENT ASSIGNEE(S): Developen Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 60pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2008006547	A2	20080117	WO 2007-EP6109		20070710
WO 2008006547	A3	20080306			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
EP 1889847	A1	20080220	EP 2006-14297		20060710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU					
PRIORITY APPLN. INFO.:			EP 2006-14297	A	20060710

OTHER SOURCE(S): MARPAT 148:168736
GI



I

AB Title compds. I [X = single bond, O, S, SO2, CH2, etc.; R1 = H, (un)substituted alkyl, alkyl-(hetero)cycloalkyl, (hetero)cycloalkyl, (hetero)aryl, etc.; R2 and R3 independently = H, (un)substituted alkyl, alkyl-(hetero)cycloalkyl, (hetero)aryl, etc.; R4 = H, (un)substituted alkyl, urea, thiourea or acetyl; R4 may form a 5- to 6-membered heterocyclyl with R1; R5-8 independently = H, halo, CN, COOH, OH, etc.; R12 = H, halo, OH, NH2, CONH or alkyl; R13 = H, alkyl, alkyoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl or acyl], and their metabolites, prodrugs or pharmaceutically acceptable salts, are prepd. and disclosed. Moreover, the invention relates to the use of I for the prodn. of pharmaceutical compns. for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. The invention compds. were evaluated for their kinase inhibitory activity. It has been shown that the particular preferred compd. of the invention exhibited IC50 values below 10 μM in in vitro bioloaical screening assays for inhibition of Mnk1 and/or Mnk2 kinase activity. I shuold prove useful for the treatment of in particular metabolic diseases of the lipid and carbohydrate metab. and the consecutive complications and disorders assocd. therewith.

IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of novel pyrrolopyrimidine compds. useful in prophylaxis, mono- and combination therapy of diseases which can be influenced by inhibition of Mnk1 or Mnk2 kinase activity)

RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (CA INDEX NAME)

L8 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1175935 CAPLUS
DOCUMENT NUMBER: 147:480410
TITLE: Thienopyrimidines having Mnk1/Mnk2 inhibiting activity
for pharmaceutical compositions
INVENTOR(S): Aicher, Babette; Coulter, Thomas Stephen; Jaekel, Stefan; Kelter, Arndt-Rene; Murfin, Stephen; Reuter, Tanja; Taylor, Steven
PATENT ASSIGNEE(S): Developen Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 95pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007115822	A1	20071018	WO 2007-EP3186	20070410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2006-7454 A 20060407

OTHER SOURCE(S): MARPAT 147:480410
AB The present invention relates to novel pharmaceutical compns. comprising thienopyrimidine compds. Moreover, the present invention relates to the use of the thienopyrimidine compds. of the invention for the production of pharmaceutical compns. for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. The present invention is more particularly directed to the treatment and/or prophylaxis of in particular metabolic diseases of the lipid and carbohydrate metabolism and the consecutive complications and disorders associated therewith.
IT 144701-48-4, Telmisartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thienopyrimidines having Mnk1/Mnk2 kinase inhibiting activity for pharmaceutical compns. for treating disease and combination with other agents)
RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (CA INDEX NAME)

L8 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1115254 CAPLUS
DOCUMENT NUMBER: 147:427340
TITLE: Benzimidazolyl-pyridine compounds for inflammation and
immune-related uses and their preparation
INVENTOR(S): Chen, Shoujun; Sun, Lijun; Xie, Yu
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 194pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007112093	A2	20071004	WO 2007-US7439	20070323
WO 2007112093	A3	20071227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070254912	A1	20071101	US 2007-726887	20070323

PRIORITY APPLN. INFO.: US 2006-785402P P 20060323

OTHER SOURCE(S): MARPAT 147:427340
GI



AB The invention relates to compds. of formula I or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof. Compds. of formula I wherein Y2 is (un)substituted alkyl, (un)substituted alkenyl,

L8 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(un)substituted cycloalkyl, (un)substituted aryl, etc.; each Z is independently (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, halo, CN, etc.; L1 is
aminoalkyl, CO, NHCO and derivs., CONH and derivs., OCO, CO2, etc.; R9 and
R10 are independently substituent; m is 0, 1, 2, 3, and 4; n is 0, 1, 2, and 3; and their pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, are claimed. These compds. are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, immune disorders, and allergic disorders. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their IL-2 prodn. inhibitory activity. From the assay, it was detd. that compd. II exhibited IC50 value of < 100 nM.
IT 880176-17-0P 880176-32-9P 880176-39-6P
880176-59-0P 880176-91-0P 880177-08-2P
880177-28-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylpyridine compds. useful as
immunosuppressive agents or in treatment and prevention of inflammatory, immune and allergic disorders)
RN 880176-17-0 CAPLUS
CN Benzamide, N-[4-[6-cyano-2-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)



RN 880176-32-9 CAPLUS
CN Benzamide, N-[4-[5-(1,1-dimethylethyl)-2-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)



RN 880176-39-6 CAPLUS
CN Benzamide, N-[4-[5,6-dimethyl-2-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)

L8 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 880176-59-0 CAPLUS
CN Benzamide,
N-[4-[2,5-bis(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)



RN 880176-91-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid,
1-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 880177-08-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide,
1-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 880177-28-6 CAPLUS
CN Benzamide,
N-[4-[5-acetyl-2-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)

L8 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1089742 CAPLUS
DOCUMENT NUMBER: 147:406840
TITLE: Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses and their preparation
INVENTOR(S): Chen, Shoujun; Jiang, Jun; Zhang, Junyi; Xie, Yu
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 169pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007109362	A2	20070927	WO 2007-US7286	20070320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070249609	A1	20071025	US 2007-726079	20070320
PRIORITY APPLN. INFO.:			US 2006-784037P P	20060320

OTHER SOURCE(S): MARPAT 147:406840
GI



AB The invention relates to compds. of structural formula I or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof. Compds. of formula I wherein X1, X2, and X3 are independently CH, CR1 and N; L is a linker; Y is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted

L8 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

cycloalkenyl, (un)substituted heterocyclyl, and (un)substituted (hetero)aryl; each Z is independently lower (halo)alkyl, halo, lower alkoxy, lower alkylsulfanyl, CN, NO2, NH2 and derivs., etc.; R1 is a substituent; R4 is H and substituent; m and n are independently 0, 1, and 2; and their pharmaceutically acceptable salts, solvated, clathrate and prodrugs thereof, are claimed. These compds. are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their IL-2 inhibitory activity. From the assay, it was detd. that compd. II exhibited an IC50 value of 6 nM.

IT 950844-47-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of benzimidazolylpyrazine compds. useful in treatment and prevention of inflammatory, allergic and immune diseases)
RN 950844-47-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid,
1-[5-[(2,6-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



IT 950844-48-1P 950844-49-2P 950844-50-5P
950844-51-6P 950844-52-7P 950844-53-8P
950844-54-9P 950844-55-0P 950844-56-1P
950844-57-2P 950844-58-3P 950844-71-0P
950844-72-1P 950844-73-2P 950844-74-3P
950844-75-4P 950844-76-5P 950844-77-6P
950844-78-7P 950844-79-8P 950844-80-1P
950844-81-2P 950844-82-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylpyrazine compds. useful in treatment and prevention of inflammatory, allergic and immune diseases)
RN 950844-48-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid,
1-[5-[[(3,5-difluoro-4-pyridinyl)carbonyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-49-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(3-fluoro-4-pyridinyl)carbonyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-50-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(3-methyl-4-pyridinyl)carbonyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-51-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2-fluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-52-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2,5-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-53-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2,4-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-54-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2,3,6-trifluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-55-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(4-chloro-2-fluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-56-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2-methylbenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-57-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2-methyl-3-pyridinyl)carbonyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-58-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-71-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(2,6-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-72-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(3,5-difluoro-4-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-73-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(3-fluoro-4-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-74-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(3-methyl-4-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-75-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(2-fluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-76-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(2,5-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-77-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(2,4-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-78-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(trifluoromethyl)-1-[5-[[(2,3,6-trifluorophenyl)methyl]amino]-2-pyrazinyl]-, methyl ester (CA INDEX NAME)



RN 950844-79-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(4-chloro-2-fluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-80-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(2-methylphenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-81-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(2-methyl-3-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950844-82-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[[(4-methyl-1,2,3-thiadiazol-5-yl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



IT 950846-05-6P 950846-06-7P 950846-07-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazolylpyrazine compds. useful in treatment and prevention of inflammatory, allergic and immune diseases)

RN 950846-05-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-(5-bromo-2-pyrazinyl)-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 950846-06-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[5-[(2,6-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 950846-07-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-(2,2-diethoxyethyl)-1-[5-[(2,6-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)

L8 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:706021 CAPLUS
DOCUMENT NUMBER: 147:125831
TITLE: Transdermal delivery of pharmaceutical agent comprising genetic molecule
INVENTOR(S): Russell-Jones, Gregory J.; Luke, Michael R.; Himes, Stewart R.
PATENT ASSIGNEE(S): Apollo Life Sciences Limited, Australia
SOURCE: PCT Int. Appl., 121pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070983	A1	20070628	WO 2006-AU1999	20061222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006326870	A1	20070628	AU 2006-326870	20061222
US 20070243132	A1	20071018	US 2006-645122	20061222
EP 1978997	A1	20081015	EP 2006-840407	20061222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2005-753454P P 20051222
AU 2006-905107 A 20060915
WO 2006-AU1999 W 20061222

AB The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic mol. or composition More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject. Thus, stable microemulsion was formed by mixing 16 g of oil (Crodamol GTCC and Capmul MCM, at 3:1 ratio) with 4 g of surfactant and cosurfactant (Brij 72 and Brij 97, at the ratio of 3:1) and stirring until clear. Water phase containing one or more water-soluble pharmaceutical agents was then added (0.5 mL). Microemulsion formation occurred following gentle shaking of the oil and water phases.

IT 68-19-9, Vitamin B12
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of pharmaceutical agent comprising genetic mol.)

RN 68-19-9 CAPLUS

L8 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN Vitamin B12 (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



IT 68-19-9D, Vitamin B12, carboxylic acid derivs. 13115-03-2, Vitamin B12-57Co 13408-78-1, Cobalamin 13408-78-1D, Cobalamin, alkylated 13422-51-0, Hydroxocobalamin 13422-52-1, Aquocobalamin 13422-53-2, Vitamin B12-60Co 13422-55-4, Methylcobalamin 13870-90-1, Adenosylcobalamin 14978-39-3, Thiocyanatocobalamin 15041-07-3, Chlorocobalamin 15671-27-9, Sulfitocobalamin 18195-32-9, Vitamin B12-58Co 20623-13-6, Nitrocobalamin 34502-77-7, Adeninylpropylcobalamin 41632-95-5, α-(5,6-Dimethylbenzimidazolyl)hydrogenobamide 55565-91-8, Vitamin B12-56Co 56226-23-4, Adeninylpentylcobalamin 59209-78-8, Adeninylethylcobalamin 114093-40-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of pharmaceutical agent comprising genetic mol.)

RN 68-19-9 CAPLUS

CN Vitamin B12 (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



RN 13115-03-2 CAPLUS
CN Vitamin B12-57Co (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 13408-78-1 CAPLUS
CN Cobinamide, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3), ion(1+) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 13408-78-1 CAPLUS
CN Cobinamide, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3), ion(1+) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 13422-51-0 CAPLUS
CN Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3)

PAGE 1-A

PAGE 2-A



RN 13422-52-1 CAPLUS
CN Cobinamide, Co-aqua-, dihydrogen phosphate (ester), inner salt, 3'-ester

L8 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3),
ion(1+), hydroxide (1:1) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



L8 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 13870-90-1 CAPLUS
CN Cobinamide, Co-(5'-deoxyadenosin-5'-yl)-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (9CI) (CA INDEX NAME)

PAGE 1-A

L8 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 3-A

RN 13422-53-2 CAPLUS
CN Vitamin B12-60Co (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 13422-55-4 CAPLUS
CN Cobinamide, Co-methyl-, dihydrogen phosphate (ester), inner salt, 3'-ester
with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (9CI) (CA INDEX NAME)

PAGE 1-A

L8 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



PAGE 3-A



RN 14978-39-3 CAPLUS
CN Cobinamide, Co-(thiocyanato-κS)-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



RN 15041-07-3 CAPLUS
CN Cobinamide, Co-chloro-, dihydrogen phosphate (ester), inner salt, 3'-ester
with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3)

salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 18195-32-9 CAPLUS

PAGE 1-A



PAGE 2-A



RN 15671-27-9 CAPLUS
CN Cobinamide, Co-(sulfito-κO)-, dihydrogen phosphate (ester), inner

CN Vitamin B12-58Co (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 20623-13-6 CAPLUS
CN Cobinamide, Co-(nitrito-κO)-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 34502-77-7 CAPLUS
CN Cobinamide, Co-[3-(6-amino-9H-purin-9-yl)propyl]-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-B



PAGE 3-A



PAGE 1-B



PAGE 2-A



PAGE 3-B



RN 41632-95-5 CAPLUS
CN Hydrogenobinamide, dihydrogen phosphate (ester), 3'-ester with 5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 55565-91-8 CAPLUS
CN Vitamin B12-56Co (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 56226-23-4 CAPLUS
CN Cobinamide, Co-[5-(6-amino-9H-purin-9-yl)pentyl]-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 59209-78-8 CAPLUS
CN Cobinamide, Co-[2-(6-amino-9H-purin-9-yl)ethyl]-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 114093-40-2 CAPLUS
CN Cobinamide, Co-(cyano-κC)-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5-methoxy-6-methyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:705477 CAPLUS
DOCUMENT NUMBER: 147:110220
TITLE: MIF inhibitors
INVENTOR(S): Morand, Eric Francis; Skene, Colin Edward; Tapley, Peter Mark; Li, Xinhua; Jozefiak, Thomas H.
PATENT ASSIGNEE(S): Cortical Pty Ltd, Australia
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070961	A1	20070628	WO 2006-AU1965	20061221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006326850	A1	20070628	AU 2006-326850	20061221
CA 2634212	A1	20070628	CA 2006-2634212	20061221
EP 1968576	A1	20080917	EP 2006-840387	20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2008090435	A	20081008	KR 2008-717792	20080721
PRIORITY APPLN. INFO.:			US 2005-752354P P	20051221
			WO 2006-AU1965 W	20061221

OTHER SOURCE(S): MARPAT 147:110220

AB The present invention relates to the use of specific benzimidazolone analogs and derivs. to inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biol. activity is implicated. Novel benzimidazole analogs and derivs. are also provided.

IT 942609-74-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MIF inhibitors)

RN 942609-74-7 CAPLUS
CN Acetic acid, 2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)

L8 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 942609-71-4P 942609-72-5P 942609-73-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MIF inhibitors)

RN 942609-71-4 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]-, methyl ester (CA INDEX NAME)



RN 942609-72-5 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-73-6 CAPLUS
CN Acetic acid, 2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]-, methyl ester (CA INDEX NAME)



IT 942609-75-8P 942609-78-1P 942609-90-7P
942609-91-8P 942609-92-9P 942609-93-0P
942609-94-1P 942609-95-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L8 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(MIF inhibitors)

RN 942609-75-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[2-[(2-hydroxyethyl)thio]acetyl]- (CA INDEX NAME)



RN 942609-78-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[2-[(6-hydroxyhexyl)thio]acetyl]- (CA INDEX NAME)



RN 942609-90-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro- (CA INDEX NAME)



RN 942609-91-8 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)

L8 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 942609-93-0 CAPLUS
CN Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 942609-95-2 CAPLUS
CN Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



IT 93202-41-6P 93202-51-8P 897545-61-8P
897545-85-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(MIF inhibitors)

RN 93202-41-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-(2-chloroacetyl)-1,3-dihydro- (CA INDEX NAME)

L8 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 93202-51-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro- (CA INDEX
NAME)



RN 897545-61-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 897545-85-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:538389 CAPLUS
DOCUMENT NUMBER: 146:521831
TITLE: Preparation of six membered heteroaromatic, particularly pyrimidine and triazine, inhibitors targeting resistant kinase mutations for treating angiogenic and hematological associated disorders
INVENTOR(S): Cao, Jianguo; Hood, John; Lohse, Dan; Mak, Chi Ching; Mc Pherson, Andrew; Noronha, Glenn; Pathak, Ved; Renick, Joel; Soll, Richard M.; Zeng, Binqi; Chow, Chun; Palanki, Moorthy; Dneprovskaia, Elena
PATENT ASSIGNEE(S): Targegen, Inc., USA
SOURCE: PCT Int. Appl., 389pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056075	A2	20070518	WO 2006-US42838	20061031
WO 2007056075	A3	20070920		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20070149508	A1	20070628	US 2006-591076	20061031
US 20070161645	A1	20070712	US 2006-591252	20061031

PRIORITY APPLN. INFO.: US 2005-733115P P 20051102

OTHER SOURCE(S): MARPAT 146:521831
GI

L8 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II



III

AB The invention is related to the preparation of heteroaroms. I [L = C6H4-[X-M-[CH(R1)]p(CH2)q[CH(R2)]nG0R3R4]; X = O, CO, SO2, CH2; M = a bond, NH and derivs.; or X-M = a bond; R1, R2 = independently at each occurrence H, CF3, F, Cl, OH, NH2, (un)substituted aryl, alkyl, etc.; or R1-R2 = a bond, (CH2)a, (CH2)m-S-(CH2)a, (CH2)m-NR9-(CH2)a, etc.; m, n, p, q, a = independently 0-6; R9 = H, (un)substituted alk(en/yn)yl, etc.; G0 = N, O, H, CH; if G0 = N, then each R3, R4 = independently H, CF3, F, Cl, Br, I, OH, OMe, CN, OCF3, NH2, (un)substituted hydroxy/amino/alkyl, (hetero)aryl, or R3-R4 = (CH2)a, (CH2)m-S-(CH2)a, (CH2)a, (CH2)m-O-(CH2)a, etc.; if G0 = N; then R1-R9, or R1-R4, or R9-R4 or R3-R4 = independently (CH2)a, (CH2)m-S-(CH2)a, (CH2)m-O-(CH2)a, etc.; if G0 = O, R3 = H, CF3, F, Br, NH2, alkyl, aryl, etc., with no group R4; R1-R9 or R1-R3 or R9-R3 = independently (CH2)a, (CH2)m-S-(CH2)a, (CH2)a, (CH2)m-O-(CH2)a, etc.; if G0 = CH, R3, R4 = independently H, CF3, CN, (un)substituted amino/hydroxy/alkyl, etc.; or R3-R4 = (CHR9)m-(CHR9)a-(CHR9)p; (CHR9)m-S-(CHR9)a, (CHR9)m-O-(CHR9)a, etc.; A = (hetero)aryl; G = N, CH, CR; R = (un)substituted alkyl; Y = CH:CH, CH2CH2] as inhibitors targeting resistant kinase mutations. Thus, bromination of 3-amino-1,2,4-triazine, Pd-coupling of the bromide with [trans-2-(3-methoxyphenyl)ethenyl]boronic acid, amination of 4-bromo-N-[2-(pyrrolidin-1-yl)ethyl]benzenesulfonamide and demethylation gave triazine II. In a luminescent assay, pyrimidine III inhibited Abl and Abl(T3151) kinases with IC50 values of 25 nM and 240 nM. I are useful for treating various angiogenic and hematol. associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications (no data).

IT 937013-20-2P 937013-22-4P, 7-[(E)-2-[2-[[4-[(Piperidin-4-yl)sulfonyl]phenyl]amino]pyrimidin-5-yl]ethenyl]-5-(trifluoromethyl)-1H-benzimidazol-2-amine

L8 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

937013-25-7P, 5-[(E)-2-[6-(Trifluoromethyl)-1H-benzimidazol-4-yl]ethenyl]-N-[4-[(piperidin-4-yl)sulfonyl]phenyl]pyrimidin-2-amine
937014-92-1P, 6-[(E)-2-[2-[[4-[(Piperidin-4-yl)sulfonyl]phenyl]amino]pyrimidin-5-yl]ethenyl]-1H-benzimidazol-2-amine
937015-69-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of six membered heteroarom., particularly pyrimidine and triazine, inhibitors targeting resistant kinase mutations)

RN 937013-20-2 CAPLUS
CN 2-Pyrimidinamine, 5-[(1E)-2-(1H-benzimidazol-6-yl)ethenyl]-N-[4-(4-piperidinylsulfonyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 937013-22-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 7-[(1E)-2-[2-[[4-(4-piperidinylsulfonyl)phenyl]amino]-5-pyrimidinyl]ethenyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 937013-25-7 CAPLUS

L8 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2-Pyrimidinamine, N-[4-(4-piperidinylsulfonyl)phenyl]-5-[(1E)-2-[5-(trifluoromethyl)-1H-benzimidazol-7-yl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 937014-92-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[(1E)-2-[2-[[4-(4-piperidinylsulfonyl)phenyl]amino]-5-pyrimidinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 937015-69-5 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-, compd. with 5-[(1E)-2-(1H-benzimidazol-6-yl)ethenyl]-N-[4-(4-piperidinylsulfonyl)phenyl]-2-pyrimidinamine (1:?) (CA INDEX NAME)

CM 1

CRN 937013-20-2
CMF C24 H24 N6 O2 S

Double bond geometry as shown.

L8 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 1493-13-6
CMF C H F3 O3 S

L8 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:351557 CAPLUS
DOCUMENT NUMBER: 146:351385
TITLE: Cell- and protein-based methods and compositions for treatment of tissue defects
INVENTOR(S): Kleinsek, Donald A.; Soto, Adriana
PATENT ASSIGNEE(S): Kleinsek, Donald, A., USA
SOURCE: PCT Int. Appl., 382 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007035843	A2	20070329	WO 2006-US36750	20060921
WO 2007035843	A3	20070705		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006292203	A1	20070329	AU 2006-292203	20060921
US 20070128174	A1	20070607	US 2006-526202	20060921
KR 2008075494	A	20080818	KR 2008-709566	20080421
PRIORITY APPLN. INFO.:			US 2005-719743P P	20050921
			WO 2006-US35676 A	20060914
			WO 2006-US36750 W	20060921

AB Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.
IT 68-19-9, Vitamin B12
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(cell- and protein-based methods and compns. for tissue defect treatment)
RN 68-19-9 CAPLUS
CN Vitamin B12 (CA INDEX NAME)

L8 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A



L8 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:982167 CAPLUS
DOCUMENT NUMBER: 145:348597
TITLE: Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
INVENTOR(S): Kohn, Leonard D.; Harii, Norikazu; Benavides-Peralta, Uruguaysito; Gonzalez-Murguiondo, Mariana; Lewis, Christopher J.; Napolitano, Giorgio; Giuliani, Cesidio; Malgor, Ramiro; Goetz, Douglas J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 102 pp., Cont.-in-part of U.S. Ser. No. 912,948.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211752	A1	20060921	US 2005-130922	20050517
US 20050209295	A1	20050922	US 2004-801986	20040316
AU 2004317993	A1	20051013	AU 2004-317993	20040316
CA 2559712	A1	20051013	CA 2004-2559712	20040316
EP 1725230	A1	20061129	EP 2004-821836	20040316
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007529510	T	20071025	JP 2007-503869	20040316
US 20060058365	A1	20060316	US 2004-912948	20040806
AU 2006247504	A1	20061123	AU 2006-247504	20060511
CA 2606769	A1	20061123	CA 2006-2606769	20060511
WO 2006124676	A1	20061123	WO 2006-US18554	20060511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1896015	A1	20080312	EP 2006-770302	20060511
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.:

US 2004-801986	A2	20040316
US 2004-912948	A2	20040806
WO 2004-US7888	A	20040316
US 2005-130922	A	20050517
WO 2006-US18554	W	20060511

OTHER SOURCE(S): MARPAT 145:348597

L8 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivs., and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.
IT 68-19-9, Vitamin B12
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; use of phenylmethimazoles, methimazole derivs., and tautomeric cyclic thiones for treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression)
RN 68-19-9 CAPLUS
CN Vitamin B12 (CA INDEX NAME)

L8 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A



L8 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:884753 CAPLUS
DOCUMENT NUMBER: 145:292717
TITLE: Preparation of 5-phenylpentanoic acid derivatives as matrix metalloproteinase inhibitors for treating asthma and other inflammatory disorders
INVENTOR(S): Palle, Venkata P.; Sattigeri, Viswajanani Jitendra; Khera, Manoj Kumar; Voleti, Sreedhara Rao; Ray, Abhijit; Dastidar, Sunanda G.
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 94pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090235	A1	20060831	WO 2006-IB349	20060221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006217615	A1	20060831	AU 2006-217615	20060221
CA 2598518	A1	20060831	CA 2006-2598518	20060221
EP 1856063	A1	20071121	EP 2006-727254	20060221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008531494	T	20080814	JP 2007-555726	20060221
MX 200710185	A	20071206	MX 2007-10185	20070821
IN 2007DN06790	A	20070928	IN 2007-DN6790	20070831
KR 2007110384	A	20071116	KR 2007-721829	20070921
CN 101151255	A	20080326	CN 2006-80010132	20070927
US 20080194565	A1	20080814	US 2008-816836	20080213

PRIORITY APPLN. INFO.:

IN 2005-DE380	A	20050222
WO 2006-IB349	W	20060221

OTHER SOURCE(S): CASREACT 145:292717; MARPAT 145:292717
GI

L8 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [X = (CH2)n; n = 1-5; R1 = (un)substituted alk(en/yn)yl, hetero/aryl, etc.; R2 = CO2H and derivs., OH and derivs., (un)substituted alkenyl, aryl, cycloalkyl, etc.; R3 = H, F, ar/cycloalkyl/alkyl; A = OH, alkoxy, NH2, etc.] were prepared as matrix metalloproteinase inhibitors. Thus, reacting tert-Bu 5-(biphenyl-4-yl)-3-oxopentanoate with benzyl aziridine-1-carboxylate, followed by reduction and Boc-deprotection gave acid
II. Activities of selected I for MM9 provided 2 nM, as compared to about 1.5 nM for marimasat. I, and their pharmaceutical compns., are useful for treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, periodontosis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase.

IT 139481-59-7, Candesartan 144701-48-4, Telmisartan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy agent; preparation of 5-phenylpentanoic acid derivs. as
matrix metalloproteinase inhibitors for treating asthma and other inflammatory disorders)

RN 139481-59-7 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

L8 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:490559 CAPLUS
DOCUMENT NUMBER: 145:8165
TITLE: Preparation of octahydropyrrolo[3,4-c]pyrrole derivatives as histamine H4 receptor ligands
INVENTOR(S): Lane, Charlotte Alice Louise; Price, David Anthony
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060111416	A1	20060525	US 2005-285653	20051121
EP 1671972	A1	20060621	EP 2004-106044	20041124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CA 2587141	A1	20060601	CA 2005-2587141	20051110
WO 2006056848	A1	20060601	WO 2005-IB3478	20051110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1846409	A1	20071024	EP 2005-824102	20051110
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008520644	T	20080619	JP 2007-542155	20051110
NL 1030503	A1	20060529	NL 2005-1030503	20051123
NL 1030503	C2	20061128		

PRIORITY APPLN. INFO.:

EP 2004-106044	A	20041124
EP 2005-100474	A	20050126
US 2005-664619P	P	20050322
WO 2005-IB3478	W	20051110

OTHER SOURCE(S): MARPAT 145:8165
GI

L8 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I II

AB The title compds. I [R1 = H, alkyl optionally substituted with hydroxy; X = N, CR9; Y = O, NH; R2-R5 = H, halo, CN, alkyl, etc.; R6 = H, Me; R9 = H, Me] which are histamine H4 receptor ligands and have therefore a number of therapeutic applications, particularly in the treatment of asthma and allergic rhinitis, were prepared Thus, reacting 1H-benzimidazole-2-carboxylic acid with (3aR,6aS)-2-methyloctahydropyrrolo[3,4-c]pyrrole afforded (3aR,6aS)-II which showed Ki of 91 nM in the H4 binding assay. The pharmaceutical compns. comprising I alone or in combination with other therapeutic agents are disclosed.

IT 1057003-32-3 1057003-34-5
RL: PRPH (Prophetic)
(Preparation of octahydropyrrolo[3,4-c]pyrrole derivatives as histamine
H4 receptor ligands)

RN 1057003-32-3 CAPLUS
CN Methanone, (5-bromo-7-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1057003-34-5 CAPLUS
CN Methanone, (5-fluoro-7-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 887779-07-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of octahydropyrrolo[3,4-c]pyrrole derivs. as histamine H4 receptor ligands)
RN 887779-07-9 CAPLUS
CN 1H-Benzimidazole-6-carboxylic acid, 2-[[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 887778-79-2P 887778-99-6P 887779-01-3P
887779-04-6P 887779-05-7P 887779-09-1P
887779-11-5P 887779-12-6P 887779-16-0P
887779-22-8P 887779-23-9P 887779-25-1P
887779-27-3P 887779-30-8P 887779-31-9P
887779-32-0P 887779-37-5P 887779-39-7P
887779-40-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of octahydropyrrolo[3,4-c]pyrrole derivs. as histamine H4 receptor ligands)
RN 887778-79-2 CAPLUS
CN Methanone, [(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl](6-methyl-1H-benzimidazol-2-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-05-7 CAPLUS
CN Methanone, (7-chloro-5-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-09-1 CAPLUS
CN Methanone, (5,6-dimethyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-11-5 CAPLUS
CN Methanone, [(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl][6-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887778-99-6 CAPLUS
CN Methanone, (6,7-dimethyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-01-3 CAPLUS
CN Methanone, [(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl](7-methyl-1H-benzimidazol-2-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-04-6 CAPLUS
CN Methanone, (5-chloro-7-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-12-6 CAPLUS
CN 1H-Benzimidazole-6-carboxylic acid, 2-[[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-16-0 CAPLUS
CN Methanone, (6-fluoro-7-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-22-8 CAPLUS
CN Methanone, (7-fluoro-5-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-23-9 CAPLUS
CN Methanone,
(6-chloro-7-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-25-1 CAPLUS
CN Methanone, (5,7-dimethyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-27-3 CAPLUS
CN Methanone, [5-fluoro-7-(trifluoromethyl)-1H-benzimidazol-2-yl][(3aR,6aS)-
hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-30-8 CAPLUS
CN Methanone,
(6-chloro-5-methyl-1H-benzimidazol-2-yl)[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-31-9 CAPLUS
CN 1H-Benzimidazole-6-carbonitrile, 2-[[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-32-0 CAPLUS
CN Methanone, [6-fluoro-5-(trifluoromethyl)-1H-benzimidazol-2-yl][(3aR,6aS)-
hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-37-5 CAPLUS
CN 1H-Benzimidazole-2-methanimine, α-[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-7-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-39-7 CAPLUS
CN 1H-Benzimidazole-2-methanimine, 6-fluoro-α-[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-7-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 887779-40-0 CAPLUS
CN 1H-Benzimidazole-2-methanimine, 6-chloro-α-[(3aR,6aS)-hexahydro-5-
methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-7-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 3584-63-2 99459-47-9,
5-Methyl-1H-benzimidazole-2-carboxylic acid 673487-31-5
673487-33-7 795296-06-9 873669-16-0
873669-20-6 887779-48-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of octahydropyrrolo[3,4-c]pyrrole derivs. as histamine H4
receptor ligands)
RN 3584-63-2 CAPLUS
CN 1H-Benzimidazole, 5,6-dimethyl-2-(trichloromethyl)- (CA INDEX NAME)



RN 99459-47-9 CAPLUS
CN 1H-Benzimidazole-2-carboxylic acid, 6-methyl- (CA INDEX NAME)



RN 673487-31-5 CAPLUS
CN 1H-Benzimidazole, 7-methyl-2-(trichloromethyl)- (CA INDEX NAME)



RN 673487-33-7 CAPLUS
CN 1H-Benzimidazole, 2-(trichloromethyl)-6-(trifluoromethyl)- (CA INDEX
NAME)



RN 795296-06-9 CAPLUS
CN 1H-Benzimidazole-6-carboxylic acid, 2-(trichloromethyl)-, methyl ester (CA INDEX NAME)



RN 873669-16-0 CAPLUS
CN 1H-Benzimidazole, 6-fluoro-7-methyl-2-(trichloromethyl)- (CA INDEX NAME)



RN 873669-20-6 CAPLUS
CN 1H-Benzimidazole, 7-chloro-5-methyl-2-(trichloromethyl)- (CA INDEX NAME)



RN 887779-48-8 CAPLUS
CN 1H-Benzimidazole, 5-chloro-7-methyl-2-(trichloromethyl)- (CA INDEX NAME)



IT 827042-57-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of octahydropyrrolo[3,4-c]pyrrole derivs. as histamine H4 receptor ligands)

RN 827042-57-9 CAPLUS
CN 1H-Benzimidazole, 6,7-dimethyl-2-(trichloromethyl)- (CA INDEX NAME)



ACCESSION NUMBER: 2006:438046 CAPLUS
DOCUMENT NUMBER: 144:468167
TITLE: Preparation of benzimidazole boronic acids and their analogs for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α)
INVENTOR(S): Burns, James F.; Cabana, Leonard A.; Collupy, Glenn C.; Didsbury, John R.; Dyakonov, Tatyana; Haydar, Simon N.; Jones, Michael L.; Li, Francine F.; Markworth, Christopher J.; Mathew, Jessymol; Schoenen, Frank J.; Vanvliet, David N.; Middlemiss, David N.
PATENT ASSIGNEE(S): Nuada, LLC, USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050053	A2	20060511	WO 2005-US38853	20051027
WO 2006050053	A3	20060706		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005302519	A1	20060511	AU 2005-302519	20051027
CA 2585766	A1	20060511	CA 2005-2585766	20051027
EP 1812451	A2	20070801	EP 2005-813762	20051027
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008518923	T	20080605	JP 2007-539145	20051027
PRIORITY APPLN. INFO.:			US 2004-624057P	P 20041101
			WO 2005-US38853	W 20051027

OTHER SOURCE(S): CASREACT 144:468167; MARPAT 144:468167
GI



I



II



III

AB The title compds. I or II [A = N or C (the proviso that R5 is absent when A = N); X = CO, SO2, a bond; Y = alkyl, cycloalkyl, aryl, etc.; Z = B(OR1)OR2, CON(R1)OR2, N(OR1)COR2; R1, R2 = H, alkyl, or together form alkylene; R3-R7 = H, halo, alkyl, etc.], useful for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof, were prepared Thus, reacting thiabendazole with 5-bromopentylboronic acid in the presence of cesium carbonate in DMF afforded 70% III which showed IC50 of 560 nM in the assay determining inhibition of TNF-α production by PMBC. Pharmaceutical formulations comprising the compound I or II are disclosed.

IT 886752-69-8P 886752-83-6P 886752-84-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole boronic acids and their analogs for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α))

RN 886752-69-8 CAPLUS
CN Boronic acid, B-[5-(5,6-dimethyl-1H-benzimidazol-1-yl)pentyl]- (CA INDEX NAME)



RN 886752-83-6 CAPLUS
CN Boronic acid, B-[5-[5-cyano-2-(4-methoxyphenyl)-1H-benzimidazol-1-yl]pentyl]- (CA INDEX NAME)

L8 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 886752-84-7 CAPLUS
CN Boronic acid, B-[5-[6-cyano-2-(4-methoxyphenyl)-1H-benzimidazol-1-yl]pentyl]- (CA INDEX NAME)



IT 582-60-5, 5,6-Dimethylbenzimidazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazole boronic acids and their analogs for inhibiting
inflammatory cytokines such as tumor necrosis factor alpha (TNF-α))
RN 582-60-5 CAPLUS
CN 1H-Benzimidazole, 5,6-dimethyl- (CA INDEX NAME)



L8 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Biological study); USES (Uses)
(kinase inhibitors for therapeutic use)
RN 31430-18-9 CAPLUS
CN Carbamic acid, N-[6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)



L8 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:13464 CAPLUS
DOCUMENT NUMBER: 144:101073
TITLE: therapeutic uses of kinase inhibitors, and compositions thereof
INVENTOR(S): Caligiuri, Maureen G.; Kley, Nikolai A.; Murthi, Krishna K.
PATENT ASSIGNEE(S): GPC Biotech, Inc., USA
SOURCE: PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002119	A2	20060105	WO 2005-US21843	20050617
WO 2006002119	A3	20070222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2584493	A1	20060105	CA 2005-2584493	20050617
EP 1763345	A2	20070321	EP 2005-762859	20050617
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 20080146555	A1	20080619	US 2007-629638	20071220
PRIORITY APPLN. INFO.:			US 2004-580868P	P 20040618
			WO 2005-US21843	W 20050617

OTHER SOURCE(S): MARPAT 144:101073
AB The invention pertains to inhibitors of various kinases (e.g. S/T kinases, Tyr kinases, etc.), which inhibitors were previously known as cyclin-dependent kinase inhibitors (CDKs). The inhibitors of the invention are capable of inhibiting various wild-type and mutant form kinases, including drug-resistant forms of mutant kinases. Thus, the kinase inhibitors are useful in treating a wide range of diseases/conditions associated with abnormal functions/excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors, and patients which are resistant or refractory to other therapeutic agents. Pharmaceutical compns. and packaged pharmaceuticals with instructions of these inhibitors and methods of using these inhibitors are also provided.
IT 31430-18-9, Nocodazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L8 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:718323 CAPLUS
DOCUMENT NUMBER: 141:242040
TITLE: Anti-CD70 antibodies and immunoconjugates with therapeutic agents for treatment of cancer and immune disorders
INVENTOR(S): Law, Che-Leung; Wahl, Alan F.; Scholler, Nathalie; Pestano, Linda A.
PATENT ASSIGNEE(S): Seattle Genetics, Inc., USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073656	A2	20040902	WO 2004-US5247	20040220
WO 2004073656	A3	20050224		
WO 2004073656	A9	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004213053	A1	20040902	AU 2004-213053	20040220
CA 2516455	A1	20040902	CA 2004-2516455	20040220
EP 1594542	A2	20051116	EP 2004-713441	20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006518753	T	20060817	JP 2006-503790	20040220
US 20060233794	A1	20061019	US 2005-546304	20050819
US 20080025989	A1	20080131	US 2007-735376	20070413
PRIORITY APPLN. INFO.:			US 2003-449055P	P 20030220
			WO 2004-US5247	A 20040220
			US 2005-546304	A2 20050819
			US 2006-792127P	P 20060413

AB Disclosed are anti-CD70 antibodies and derivs. thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compns. and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunol. disorders, comprising administering to a subject the disclosed pharmaceutical compns.
IT 31430-18-9D, Nocodazole, conjugates
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-CD70 antibodies and immunoconjugates with therapeutic agents for treatment of cancer and immune disorders)
RN 31430-18-9 CAPLUS
CN Carbamic acid, N-[6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)

L8 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:515475 CAPLUS
DOCUMENT NUMBER: 141:71360
TITLE: Preparation of derivatives of and analogs of dibenzosuberone for use in pharmaceutical compositions as steroid hormone nuclear receptor modulators
INVENTOR(S): Coghlan, Michael Joseph; Green, Jonathan Edward; Grese, Timothy Alan; Jadhav, Prabhakar Kondaji; Matthews, Donald Paul; Steinberg, Mitchell Irvin; Fales, Kevin Robert; Bell, Michael Gregory
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 457 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052847	A2	20040624	WO 2003-US16213	20030613
WO 2004052847	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489276	A1	20040624	CA 2003-2489276	20030613
AU 2003302220	A1	20040630	AU 2003-302220	20030613
BR 2003012095	A	20050329	BR 2003-12095	20030613
EP 1519915	A2	20050406	EP 2003-810038	20030613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665780	A	20050907	CN 2003-815098	20030613
CN 1331848	C	20070815		
JP 2005539088	T	20051222	JP 2004-559025	20030613
CN 101161641	A	20080416	CN 2007-10112172	20030613
US 20060063759	A1	20060323	US 2004-517010	20041203
US 7411072	B2	20080812		
IN 2004KN01910	A	20070126	IN 2004-KN1910	20041213
MX 2004PA12998	A	20050516	MX 2004-PA12998	20041217
ZA 2004010293	A	20060222	ZA 2004-10293	20041221
NO 2005000397	A	20050304	NO 2005-397	20050125

PRIORITY APPLN. INFO.:		
US 2002-391992P	P	20020626
CN 2003-815098	A3	20030613
WO 2003-US16213	W	20030613

OTHER SOURCE(S): MARPAT 141:71360
GI

L8 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I II

AB Dibenzosuberone derivs., such as I [X = CH2; R, R1 = H, OH, CN, halogen, alkoxy, sulfonylamino, amino, etc.; R2 = aryl, heteroaryl; R3 = H, alkyl], and heterocyclic analogs thereof, such as I [X = O, S, NH, NMe, etc.], were prepared for therapeutic use in the treatment of pathol. disorders susceptible to steroid hormone nuclear receptor modulation. These compds. are claimed for use the treatment of disorders, such as Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic. congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melan in pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease,. Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis,. Bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus,, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multipie sclerosis. Thus, dibenzosuberone deriv. II (R = NHMe) was prepd. with 48% yield via reaction of the corresponding sulfonyl chloride II (R = Cl) with MeNH2 in THF. The prepd. dibenzosuberone derivs. and analogs were assayed for mineralocorticoid and glucocorticoid receptor binding.

IT 710341-98-3P 710344-04-0P 710344-05-1P
710344-06-2P 710344-08-4P 710344-10-8P
710344-13-1P 710344-14-2P 710344-17-5P
710344-18-6P 710344-19-7P 710344-20-0P
710344-21-1P 710344-24-4P 710344-26-6P
710344-27-7P 710344-28-8P 710344-29-9P
710344-30-2P 710344-31-3P 710344-35-7P
710344-37-9P 710344-38-0P 710344-51-7P
710344-75-5P 710345-04-3P 710345-27-0P
710345-35-0P 710345-37-2P 710345-64-5P
710345-65-6P 710345-66-7P 710345-69-0P
710345-76-9P 710345-77-0P 710345-78-1P
710345-79-2P 710345-80-5P 710345-81-6P
710345-82-7P 710345-83-8P 710345-84-9P
710345-85-0P 710345-86-1P 710345-92-9P
710345-93-0P 710346-00-2P 710346-01-3P
710346-04-6P 710346-06-8P 710346-07-9P
710346-08-0P 710346-09-1P 710346-10-4P
710346-11-5P 710346-12-6P 710346-63-7P
710346-64-8P 710346-65-9P 710346-66-0P
710346-67-1P 710346-68-2P 710346-69-3P
710346-70-6P 710346-71-7P 710347-80-1P
710347-81-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of derivs. and heterocyclic analogs of dibenzosuberone for use in pharmaceutical compns. as steroid hormone nuclear receptor modulators)

RN 710341-98-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-04-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710344-05-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-06-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 710344-14-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-17-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-[2-(difluoromethyl)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-18-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-[2-(difluoromethyl)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-08-4 CAPLUS
CN 1H-Benzimidazole, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



RN 710344-10-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



RN 710344-13-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.

Double bond geometry as shown.



RN 710344-19-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)



RN 710344-20-0 CAPLUS
CN 5H-Dibenzo[a,d]cycloheptene-2-carbonitrile, 5-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)methylene]-10,11-dihydro-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-21-1 CAPLUS
CN 5H-Dibenzo[a,d]cycloheptene-2-carbonitrile, 5-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)methylene]-10,11-dihydro-, (5E)- (CA INDEX NAME)

L8 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Double bond geometry as shown.



RN 710344-24-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)



RN 710344-26-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



L8 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-31-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(4-chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-35-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(1,9-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-37-9 CAPLUS

L8 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 710344-27-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(2-fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-28-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,4-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710344-29-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 710344-30-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(4-chloro-10,11-dihydro-5H-

L8 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2H-Benzimidazol-2-one, 5-[(E)-[10,11-dihydro-2-(trifluoromethyl)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-38-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-[10,11-dihydro-2-(trifluoromethyl)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-51-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710344-75-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-04-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2-chloro-7-fluoro-4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-27-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-35-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(7-fluoro-4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710345-37-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(7-fluoro-4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710345-64-5 CAPLUS
CN 5H-Benzo[4,5]cyclohepta[1,2-b]pyridine-2-carbonitrile, 5-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)methylene]-8-fluoro-10,11-dihydro- (CA INDEX NAME)



RN 710345-65-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 710345-66-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-cyclopropyl-5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-69-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-76-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-77-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 710345-78-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-cyclopropyl-5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-79-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-80-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 710345-81-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-82-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-83-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-84-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-85-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-86-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(8-fluoro[1]benzoxepino[3,4-b]pyridin-5(11H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 710345-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(8-fluoro[1]benzoxepino[3,4-b]pyridin-5(11H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710345-93-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-(dibenz[b,e]oxepin-11(6H)-ylidenemethyl)-1,3-dihydro- (CA INDEX NAME)



RN 710346-00-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-01-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-04-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[(3-methoxydibenz[b,e]oxepin-11(6H)-ylidene)methyl]- (CA INDEX NAME)



RN 710346-06-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(8-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-07-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(4-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-08-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[3-(trifluoromethyl)dibenz[b,e]oxepin-11(6H)-ylidene]methyl]- (CA INDEX NAME)



RN 710346-09-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-10-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 710346-11-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710346-12-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 710346-63-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-64-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-65-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(7-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-66-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(9-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RN 710346-67-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(9-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-68-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(Z)-(9-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 710346-69-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 710346-70-6 CAPLUS
CN 2H-Benzimidazol-2-one,
5-[(Z)-(7-fluoro[1]benzoxepino[3,4-d]thiazol-10(4H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710347-81-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(5Z)-1-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



Double bond geometry as shown.



RN 710346-71-7 CAPLUS
CN 2H-Benzimidazol-2-one,
5-[(E)-(7-fluoro[1]benzoxepino[3,4-d]thiazol-10(4H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 710347-80-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(5E)-1-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.

ACCESSION NUMBER: 2003:991486 CAPLUS
DOCUMENT NUMBER: 140:27827
TITLE: Preparation of benzimidazole derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
INVENTOR(S): Morand, Eric Francis; Iskander, Magdy Naguib
PATENT ASSIGNEE(S): Cortical Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104203	A1	20031218	WO 2003-AU717	20030606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487838	A1	20031218	CA 2003-2487838	20030606
AU 2003233244	A1	20031222	AU 2003-233244	20030606
GB 2405147	A	20050223	GB 2004-27242	20030606
GB 2405147	B	20061122		
EP 1511736	A1	20050309	EP 2003-727010	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675185	A	20050928	CN 2003-818935	20030606
JP 2005533049	T	20051104	JP 2004-511273	20030606
NZ 537301	A	20060630	NZ 2003-537301	20030606
IN 2004KN01848	A	20060804	IN 2004-KN1848	20041206
ZA 2004009845	A	20060927	ZA 2004-9845	20041206
US 20060154977	A1	20060713	US 2005-517264	20050930

PRIORITY APPLN. INFO.: AU 2002-2832 A 20020607
AU 2002-2834 A 20020607
WO 2003-AU717 W 20030606

OTHER SOURCE(S): MARPAT 140:27827
GI



I

AB Title compds. I [X = O, S, alkyl, amino; Y = amino, O, S, alkyl; Z = CO, CS, imino, SO, SO2; R1 = H, alkyl, alkyloxy, etc.; R2 = alkyl, alkenyl, alkynyl, etc.; R3 = H, alkyl, alkylamino, alkylalkoxy, etc.; R4 = H, halo, alkyl, alkenyl, alkynyl, etc.] are prepared For instance, 3,4-diaminotoluene is reacted with urea (pentanol, reflux) to give 5-methylbenzimidazol-2-one (56%). Example compds. are inhibitors of the cytokine or biol. activity of macrophage migration inhibitory factor (MIF). I are useful for the treatment of Lyme disease, connective tissue diseases, etc.

IT 5400-75-9P 23814-14-4P 67014-36-2P
83573-62-0P 634602-85-0P 634602-87-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzimidazoles which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))

RN 5400-75-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-methyl- (CA INDEX NAME)



RN 23814-14-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 67014-36-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-amino-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 83573-62-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-methyl-6-nitro- (CA INDEX NAME)



RN 634602-85-0 CAPLUS
CN L-Serine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-87-2 CAPLUS
CN L-Phenylalanine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 36896-35-2P 58089-25-1P 100253-32-5P
106429-57-6P 634602-82-7P 634602-83-8P
634602-84-9P 634602-86-1P 634602-88-3P
634602-89-4P 634602-90-7P 634602-91-8P
634602-92-9P 634602-93-0P 634602-94-1P
634602-95-2P 634602-96-3P 634602-97-4P
634603-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzimidazoles which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))

RN 36896-35-2 CAPLUS
CN 1H-Benzimidazole-5-pentanoic acid, 2,3-dihydro-δ,2-dioxo- (CA INDEX NAME)



RN 58089-25-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo- (CA INDEX NAME)



RN 100253-32-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-pentyl- (CA INDEX NAME)



RN 106429-57-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, methyl ester (CA INDEX NAME)



RN 634602-82-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, pentyl ester (CA INDEX NAME)



RN 634602-83-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, 2-(2-hydroxyethoxy)ethyl ester (CA INDEX NAME)



RN 634602-84-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)



RN 634602-86-1 CAPLUS
CN L-Serine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-88-3 CAPLUS
CN L-Phenylalanine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 634602-89-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 634602-90-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)



RN 634602-91-8 CAPLUS
CN β-D-Glucopyranose, 2,3,4,6-tetraacetate 1-(2,3-dihydro-2-oxo-1H-benzimidazole-5-carboxylate) (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-bromo-1,3-dihydro-6-methyl- (CA INDEX NAME)

L8 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 634602-93-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-hydroxy-6-methyl- (CA INDEX NAME)



RN 634602-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-tridecyl- (CA INDEX NAME)



RN 634602-95-2 CAPLUS
CN 2H-Benzimidazol-2-one, 4,5,7-tribromo-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 634602-96-3 CAPLUS
CN Acetamide, N-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-5-yl)-2-(2-pyrimidinylthio)- (CA INDEX NAME)



RN 634602-97-4 CAPLUS
CN 1H-Benzimidazole-5-carbothioic acid, 2,3-dihydro-2-oxo-, S-pentyl ester

L8 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



RN 634603-00-2 CAPLUS
CN 1H-Benzimidazole-5-carboximidamide, N-butyl-2,3-dihydro-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:319442 CAPLUS
DOCUMENT NUMBER: 138:314583
TITLE: Methods using highly effective inhibition of the renin-angiotensin system for protecting tissue from the effects of angiotensin II
INVENTOR(S): Weinberg, Marc S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030078190	A1	20030424	US 2002-155824	20020524
PRIORITY APPLN. INFO.:			US 2001-293835P	P 20010525

AB Methods and pharmaceutical compns. are provided for protecting tissue of a subject from the effects of angiotensin II. The methods involve administering to subjects angiotensin receptor blockers (ARB), either by themselves at doses beyond those recommended or effective for the management of hypertension, or in combination with angiotensin-converting enzyme inhibitors (ACEI). The pharmaceutical compns. include both an ARB and an ACEI and are formulated in certain preferred embodiments for once-daily oral administration. The methods and pharmaceutical compns. are useful for the treatment of proteinuria, chronic or congestive heart failure, aneurysms, and vascular tissue hypertrophy.

IT 139481-59-7, Candesartan 139481-59-7D, Candesartan, prodrug derivs. 144701-48-4, Telmisartan 144701-48-4D, Telmisartan, prodrug derivs. 145040-37-5, Candesartan cilexetil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(renin-angiotensin system inhibition for protecting tissue from effects of angiotensin II)

RN 139481-59-7 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 139481-59-7 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX

L8 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (CA
INDEX NAME)



RN 144701-48-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (CA
INDEX NAME)

L8 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

L8 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 145040-37-5 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid,
2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-,
1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:819234 CAPLUS
DOCUMENT NUMBER: 132:59191
TITLE: Therapeutic methods employing disulfide derivatives
of
dithiocarbamates and compositions useful therefor
INVENTOR(S): Lai, Ching-San; Vassilev, Vassil
PATENT ASSIGNEE(S): Medinox, Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966918	A1	19991229	WO 1999-US14237	19990622
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6093743	A	20000725	US 1998-103639	19980623
CA 2335858	A1	19991229	CA 1999-2335858	19990622
AU 9947119	A	20000110	AU 1999-47119	19990622
AU 762680	B2	20030703		
EP 1089723	A1	20010411	EP 1999-930617	19990622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518441	T	20020625	JP 2000-555604	19990622
US 6316502	B1	20011113	US 2000-565666	20000505
PRIORITY APPLN. INFO.:			US 1998-103639	A2 19980623
			WO 1999-US14237	W 19990622

OTHER SOURCE(S): MARPAT 132:59191
AB The invention provides a dithiocarbamate disulfide dimer useful in
various
therapeutic treatments, either alone or in combination with other active
agents. In one method, the disulfide derivative of a dithiocarbamate is
coadministered with an agent that inactivates (or inhibits the
production of)
species that induce the expression of nitric oxide synthase to reduce the
production of such species, while, at the same time reducing nitric oxide
levels in the subject. In another embodiment, free iron ion levels are
reduced in a subject by administration of a disulfide derivative of a
dithiocarbamate(s) to scavenge free iron ions, for example, in subjects
undergoing anthracycline chemotherapy. In another embodiment, cyanide
levels are reduced in a subject by administration of a disulfide
derivative of
a dithiocarbamate so as to bind cyanide in the subject. In a further
aspect, the present invention relates to compns. and formulations useful
in such therapeutic methods.
IT 13422-51-0, Hydroxocobalamin
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(dithiocarbamate disulfides, alone or with other agents, for therapeutic use)
RN 13422-51-0 CAPLUS
CN Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN3)
(CA INDEX NAME)

PAGE 1-A

PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 1998:112229 CAPLUS
DOCUMENT NUMBER: 128:192667
ORIGINAL REFERENCE NO.: 128:38067a,38070a
TITLE: Preparation of substituted aromatic compounds as inhibitors of tumor necrosis factor and cyclic AMP phosphodiesterase
INVENTOR(S): He, Wei; Hulme, Christopher; Huang, Fu-chih; Djuric, Stevan W.; Moriarty, Kevin; Labaudiniere, Richard
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA; He, Wei; Hulme, Christopher; Huang, Fu-Chih; Djuric, Stevan W.; Moriarty, Kevin; Labaudiniere, Richard
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805327	A1	19980212	WO 1997-US13343	19970722
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9738990	A	19980225	AU 1997-38990	19970722
PRIORITY APPLN. INFO.:			US 1996-23165P P	19960805
			WO 1997-US13343 W	19970722

OTHER SOURCE(S): MARPAT 128:192667
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention is directed to compound of formula [I; ring A = Q10, Q11; Ar1
= Q12, Q13, Q14; ring Ar2 = (un)substituted fused Ph or fused monocyclic heteroaryl; R = (un)substituted alkyl, aralkyl, or heteroaralkyl, arylsulfonyl, heteroarylsulfonyl, etc.; R1 = carboxyalkyl, alkoxycarbonylalkyl, N-(un)substituted carbamoylalkyl, cyanoalkyl, (un)substituted aralkyl or heteroaralkyl; R2 = (un)substituted lower alkyl; R3 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or oxaaliph., (un)substituted or optionally oxidized cyclothioalkyl or cyclothioalkenyl; R4, R6 = H, (un)substituted lower alkyl; R5 = (un)substituted alkyl, alkoxy, cycloalkyl, or heterocyclyl, alkoxycarbonyl, cyano, (un)substituted carbamoyl, (un)substituted aryl or heteroaryl, or CO2H where m is other than 0; R7 = H, alkoxy, (un)substituted cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, alkylthio, or alkylsulfinyl, etc.; Q1, Q2 = CH2, O-(un)substituted CHOH, CO; Q3, Q4, Q5, Q9 = N, optionally halo-substituted CH; Q6 = N, CH; Q7-C-Q8 = N-(un)saturated NHCH:N, O-CH:CH, CH:CH-O, O-CH2CH2, CH2CH2O; Z', Z''

= H or Z'Z'' = O or S; Z1, Z2 = direct bond, O, S; Z3 = SO2, direct bond; Z4 = direct bond, O, S, NH; Z5 = direct bond, (un)substituted lower alkenyl; m, n = 0, 1; p = 1-3; q = 0-5] or hydrate, solvate, N-oxide, or prodrug thereof or a pharmaceutically acceptable salt thereof are. They are esp. useful for inhibiting the prodn. or physiol. effects of tumor necrosis factor (TNF) and inhibit cAMP phosphodiesterase and are useful for the treatment of disease states assocd. with abnormally high physiol. levels of cytokines such as TNF or those assocd. with pathol. (e.g. asthma as bronchodilators or inflammation) conditions that are modulated by inhibiting enzymes such as cAMP phosphodiesterase (no data). In particular, they are used for treating a disease state capable of being
modulated by inhibiting TNF, e.g., joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis and osteoarthritis, sepsis, septic shock, gram neg. sepsis, toxic shock syndrome, acute respiratory distress syndrome, asthma, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejection malaria, myalgias, HIV, AIDS, cachexia, Crohn's disease, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus, psoriasis, Behcet's disease,
anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease, and leukemia. They are also used for treating a pathol. condition assocd. with a function of cAMP phosphodiesterase, eosinophil accumulation or function of the eosinophil, e.g., asthma, atopic dermatitis, urticaria, allergic rhinitis, psoriasis, rheumatic arthritis, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome, diabetes insipidus, keratosis, dermatitis, cerebral senility, multiinfarct dementia, senile dementia, memory impairment assocd. with Parkinson's disease, cardiac arrest, stroke, and intermittent
claudication. The present invention is also directed to their pharmaceutical use, pharmaceutical compns. contg. the compds., and methods of their prepn. Thus, 2-(3-cyclopentyloxy-4-methoxyphenyl)-5-hydroxymethyl-2-(4-pyridylmethyl)indan-1,3-dione was treated with NaH in THF, tosylated by tosyl chloride at 0° to room temp. for 2 h, and then condensed with 1-methylpiperazine in the K2CO3 in acetone at room temp. for 4 days the presence of K2CO3 in acetone to give the title compd., piperazinylmethylpyridylmethylindandione deriv. (II).

IT 201287-03-8P 201287-04-9P 201287-05-0P
201287-06-1P 201287-07-2P 201287-08-3P
201287-09-4P 201287-10-7P 201287-11-8P
201287-12-9P 201287-13-0P 201287-14-1P
201287-15-2P 201287-16-3P 201287-17-4P
201287-18-5P 201287-20-9P 201287-21-0P
201287-22-1P 201287-23-2P 201287-24-3P
201287-25-4P 201287-26-5P 201287-27-6P
201287-28-7P 201287-29-8P 201287-30-1P
201287-31-2P 201287-32-3P 201287-33-4P
201287-34-5P 201287-35-6P 201287-36-7P
201287-37-8P 201287-38-9P 201287-39-0P
201287-40-3P 201287-41-4P 201287-42-5P
201287-43-6P 201287-44-7P 201287-45-8P
201287-46-9P 201287-67-4P 201287-68-5P
201287-69-6P 201287-74-3P 201287-75-4P
201287-76-5P 201287-77-6P 203441-55-8P
203441-56-9P 203441-57-0P 203441-58-1P
203441-59-2P

L8 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of substituted arom. compds. as inhibitors of tumor necrosis factor and cAMP phosphodiesterase)
RN 201287-03-8 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxymethyl)- (CA INDEX NAME)



RN 201287-04-9 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-phenyl- (CA INDEX NAME)



RN 201287-05-0 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylethyl)- (CA INDEX NAME)



RN 201287-06-1 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenylmethyl)- (CA INDEX
NAME)

L8 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 201287-07-2 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-phenylethyl)- (CA INDEX NAME)



RN 201287-08-3 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenyl)methyl]-
(CA INDEX NAME)



RN 201287-09-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-(1,2-diphenylethyl)-7-methoxy- (CA INDEX NAME)



RN 201287-10-7 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylpropyl)- (CA

L8 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)



RN 201287-11-8 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenoxy)methyl]- (CA INDEX NAME)



RN 201287-12-9 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-phenylbutyl)- (CA INDEX NAME)



RN 201287-13-0 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-[(4-bromophenyl)methyl]-7-methoxy-
(CA INDEX NAME)



RN 201287-14-1 CAPLUS

L8 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-methoxy-1-phenylpropyl)- (CA INDEX NAME)



RN 201287-15-2 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-[(4-cyanophenyl)methyl]-7-methoxy-
(CA INDEX NAME)



RN 201287-16-3 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)



RN 201287-17-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(2-methoxyphenyl)methyl]-
(CA INDEX NAME)



RN 201287-18-5 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxyphenylmethyl)- (CA INDEX NAME)



RN 201287-20-9 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-methyl- (CA INDEX NAME)



RN 201287-21-0 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenoxymethyl)- (CA INDEX NAME)



RN 201287-22-1 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-cyclopentyl-7-methoxy- (CA INDEX NAME)



RN 201287-23-2 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-(phenylmethyl)- (CA INDEX NAME)



RN 201287-24-3 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-cyclopentyl-7-methoxy-1-methyl- (CA INDEX NAME)



RN 201287-25-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2,7-dimethoxy- (CA INDEX NAME)



RN 201287-26-5 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-cyclopropyl-7-methoxy- (CA INDEX NAME)



RN 201287-27-6 CAPLUS

CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxymethyl)-, methyl ester (CA INDEX NAME)



RN 201287-28-7 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-phenyl-, methyl ester (CA INDEX NAME)



RN 201287-29-8 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylethyl)-, methyl ester (CA INDEX NAME)



RN 201287-30-1 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenylmethyl)-, methyl ester (CA INDEX NAME)



RN 201287-31-2 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-phenylethyl)-, methyl ester (CA INDEX NAME)



RN 201287-32-3 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)



RN 201287-33-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-(cyclohexylphenylmethyl)-7-methoxy-, methyl ester (CA INDEX NAME)



RN 201287-34-5 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-(1,2-diphenylethyl)-7-methoxy-, methyl ester (CA INDEX NAME)



RN 201287-35-6 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylpropyl)-, methyl ester (CA INDEX NAME)



RN 201287-36-7 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenoxy)methyl]-, methyl ester (CA INDEX NAME)



RN 201287-37-8 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-phenylbutyl)-, methyl ester (CA INDEX NAME)



RN 201287-38-9 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-[(4-bromophenyl)methyl]-7-methoxy-, methyl ester (CA INDEX NAME)



RN 201287-39-0 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-methoxy-1-phenylpropyl)-, methyl ester (CA INDEX NAME)



RN 201287-40-3 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(2-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)



RN 201287-41-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(2-methoxyphenoxy)methyl]-, methyl ester (CA INDEX NAME)



RN 201287-42-5 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-methyl-, methyl ester (CA
INDEX NAME)



RN 201287-43-6 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenoxymethyl)-, methyl ester (CA INDEX NAME)



RN 201287-44-7 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-cyclopentyl-7-methoxy-, methyl ester
(CA INDEX NAME)



RN 201287-45-8 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-(phenylmethyl)-, methyl ester (CA INDEX NAME)



RN 201287-46-9 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-cyclopropyl-7-methoxy-, methyl ester
(CA INDEX NAME)



RN 201287-67-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-cyclopentyl-7-methoxy-1-methyl-, methyl ester (CA INDEX NAME)



RN 201287-68-5 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-cyclopentyl-4-methoxy-1-methyl-, methyl ester (CA INDEX NAME)



RN 201287-69-6 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2,7-dimethoxy-, methyl ester (CA INDEX NAME)



RN 201287-74-3 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxyphenylmethyl)-, methyl ester (CA INDEX NAME)



RN 201287-75-4 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-pyridinyl)-, methyl ester (CA INDEX NAME)



RN 201287-76-5 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-[(4-cyanophenyl)methyl]-7-methoxy-, methyl ester (CA INDEX NAME)



RN 201287-77-6 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[[4-(3-pyridinyl)phenyl]methyl]-, methyl ester (CA INDEX NAME)



RN 203441-55-8 CAPLUS
CN 1H-Benzimidazole-4-acetic acid, 7-methoxy-2-(methoxymethyl)- (CA INDEX NAME)



RN 203441-56-9 CAPLUS
CN 1H-Benzimidazole-4-carbonyl chloride, 7-methoxy-2-(methoxymethyl)- (CA INDEX NAME)



RN 203441-57-0 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 2-(cyclohexylphenylmethyl)-7-methoxy-
(CA INDEX NAME)



RN 203441-58-1 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-methylethoxy)- (CA INDEX NAME)



L8 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 203441-59-2 CAPLUS
CN 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-methylethyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   119.88     298.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -16.00     -16.00

STN INTERNATIONAL LOGOFF AT 13:12:14 ON 18 NOV 2008
```